Burzynski Research Institute, Inc Announces Board Changes
October 06, 2021 at 09:16 pm
Share
On October 6, 2021, the board of directors of Burzynski Research Institute, Inc. appointed Monika Szopa-Paszkowiak to the Board, to fill a vacancy as a result of the passing away of Dr. Barbara Burzynski, effective as of the same date, to serve until her successor is duly appointed and qualified, or her earlier death, resignation or removal. Ms. Szopa-Paszkowiak is currently a real estate agent with Coldwell Banker and also assists with her husband’s medical practice in Oklahoma. Prior to her current occupations, Ms. Szopa-Paszkowiak assisted the Company with pharmaceutical manufacturing and procurement of active ingredients and equipment necessary for the manufacture of Antineoplaston formulations. She had also worked with patients and directed the Human Resources Department at Burzynski Clinic. She is the step-daughter of Dr. Stanislaw R. Burzynski, who currently serves as the President and Chairman of the Company. Ms. Szopa-Paszkowiak is expected to be a valuable member of the Board.
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.
BURZYNSKI RESEARCH INSTITUTE, INC. 
